# OnCo record epcoritamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/epcoritamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "epcoritamab" ;
  schema:name "Epcoritamab"@en ;
  schema:description "Epcoritamab is an under-the-skin injection that pulls T cells onto lymphoma cells; it is approved for relapsed large B-cell and follicular lymphoma, and moving toward first line."@en ;
  schema:url <https://onco.cc/drugs/epcoritamab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Epcoritamab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q119025940> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Epcoritamab> ;
  onco:status "approved" ;
  onco:modality "Bispecific T-cell engager (CD20×CD3)" ;
  schema:alternateName "Epkinly" ;
  onco:approval "US 2023: Relapsed/refractory DLBCL or high-grade B-cell lymphoma after ≥2 lines (accelerated)", "US 2024: Relapsed/refractory follicular lymphoma after ≥2 lines (accelerated; full 2025 with R2)", "EU 2023: EU brand Tepkinly" ;
  onco:acceleratedApproval "US 2023-05-19: Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.", "US 2024-06-24: Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy" ;
  onco:acceleratedApprovalConfirmed "US 2025-11-18: Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/genmab/>, <https://onco.cc/companies/abbvie/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/step-up-dosing/> ;
  onco:trials <https://onco.cc/trials/epcore-nhl-1/>, <https://onco.cc/trials/epcore-dlbcl-1/>, <https://onco.cc/trials/epcore-dlbcl-2/>, <https://onco.cc/trials/nct07226752/>, <https://onco.cc/trials/nct06508658/>, <https://onco.cc/trials/nct06191744/>, <https://onco.cc/trials/nct05409066/>, <https://onco.cc/trials/nct06090539/>, <https://onco.cc/trials/nct04542824/>, <https://onco.cc/trials/nct05201248/>, <https://onco.cc/trials/nct05451810/>, <https://onco.cc/trials/nct05283720/>, <https://onco.cc/trials/nct04623541/> .